Diabetic nephropathy (DN) is one of the common microvascular complications of diabetes. Autotaxin (ATX) is an enzyme with lysophospholipase D activity, producing lysophosphatidic acid (LPA). LPA signaling has been implicated in renal fibrosis, thereby inducing renal dysfunction. BBT-877 is an orally administered small molecule inhibitor of ATX. However, its effect on DN has not been studied so far. In this study, we investigated the effect of BBT-877, a novel inhibitor of ATX, on the pathogenesis of DN in a mouse model of streptozotocin (STZ)-induced diabetes.

中文翻译：

---

新型ATX抑制剂BBT-877对1型糖尿病肾病小鼠模型的影响

糖尿病肾病（DN）是糖尿病常见的微血管并发症之一。自分泌运动因子 (ATX) 是一种具有溶血磷脂酶 D 活性的酶，可产生溶血磷脂酸 (LPA)。LPA 信号传导与肾纤维化有关，从而诱发肾功能障碍。BBT-877 是一种口服 ATX 小分子抑制剂。但目前尚未研究其对DN的影响。在这项研究中，我们在链脲佐菌素 (STZ) 诱导的糖尿病小鼠模型中研究了 BBT-877（一种新型 ATX 抑制剂）对 DN 发病机制的影响。